X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody, which demonstrates high selectivity towards its target in human blood, investigated for the treatment of Pyoderma Gangrenosum.
Lead Product(s): Ifx-1
Therapeutic Area: Dermatology Product Name: Gohibic
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody, which demonstrates high selectivity towards its target in human blood, used for the treatment of Critically Ill COVID-19 Patients.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: Gohibic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2023
Details:
Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody that has been granted an approval for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: Gohibic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2023
Details:
Under the terms of the agreement, WuXi Biologics will provide cGMP manufacturing of Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody for the treatment of COVID-19.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: Gohibic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: InflaRx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 16, 2023
Details:
The Company intends to use the net proceeds from the offering to fund the continued development of IFX-1 (vilobelimab), a chimeric monoclonal IgG4 antibody that specifically binds with high affinity to the soluble form of human C5a.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Raymond James & Associates
Deal Size: $46.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 18, 2023
Details:
The Company intends to use the net proceeds from the offering to fund the continued development of IFX-1 (vilobelimab),a chimeric monoclonal IgG4 antibody that specifically binds with high affinity to the soluble form of human C5a.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Raymond James & Associates
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 14, 2023
Details:
The Company intends to use the net proceeds from the offering to fund the continued development of IFX-1 (vilobelimab), an anti-C5a monoclonal antibody, in patients with severe COVID-19.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Raymond James & Associates
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 11, 2023
Details:
Gohibic (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody that has been granted an EUA for the treatment of COVID-19 in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: Gohibic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2023
Details:
IFX-1 (Vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
Lead Product(s): Ifx-1
Therapeutic Area: Dermatology Product Name: IFX-1
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
Vilobelimab (IFX-1) is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
Details:
The published data show that IFX-1 (vilobelimab) treatment improved survival with a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo in the global data set.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2022
Details:
IFX-1 (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2022
Details:
IFX-1 (vilobelimab), is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
Lead Product(s): Ifx-1
Therapeutic Area: Rare Diseases and Disorders Product Name: IFX-1
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2022
Details:
Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
Lead Product(s): Ifx-1
Therapeutic Area: Dermatology Product Name: IFX-1
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
IFX-1 (vilobelimab) is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
Lead Product(s): Ifx-1
Therapeutic Area: Dermatology Product Name: IFX-1
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2022
Details:
Vilobelimab, a monoclonal anti-human complement factor C5a antibody, highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood for treatment in patients with ulcerative pyoderma gangrenosum.
Lead Product(s): Ifx-1
Therapeutic Area: Dermatology Product Name: IFX-1
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innovaderm Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
Lead Product(s): Ifx-1
Therapeutic Area: Dermatology Product Name: IFX-1
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2022
Details:
In IFX-1 (vilobelimab), monoclonal anti-human complement factor C5a antibody, and pembrolizumab combination arm, the three patients enrolled in the first dosing cohort have been treated for 36 days with no safety concerns.
Lead Product(s): Ifx-1,Pembrolizumab
Therapeutic Area: Oncology Product Name: IFX-1
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2022
Details:
The purpose of the grant is to advance clinical development activities in COVID-19 and to secure manufacturing capacity for vilobelimab in Germany and support the development of vilobelimab for the treatment of severely ill, mechanically ventilated COVID-19 patients.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: German Federal Government
Deal Size: $50.7 million Upfront Cash: Undisclosed
Deal Type: Funding October 19, 2021
Details:
The Phase II of the study evaluated vilobelimab treatment plus supportive care compared to supportive care alone for up to 28 days. Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which effectively blocks the biological activity of C5a.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Details:
Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which highly and effectively blocks the biological activity of C5a and demonstrates high selectivity towards its target in human blood.
Lead Product(s): Ifx-1
Therapeutic Area: Dermatology Product Name: IFX-1
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 08, 2021
Details:
The study will investigate two independent arms: vilobelimab alone and vilobelimab in combination with pembrolizumab. The trial will assess the safety and antitumor activity of vilobelimab monotherapy and determine the recommended dose, safety in combination arm.
Lead Product(s): Ifx-1,Pembrolizumab
Therapeutic Area: Oncology Product Name: IFX-1
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2021
Details:
The main objectives of the study are the evaluation of the safety and efficacy of vilobelimab in patients with PG. Target enrollment of 18 patients reached across three different dose groups.
Lead Product(s): Ifx-1
Therapeutic Area: Dermatology Product Name: IFX-1
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2021
Details:
Company has decided to continue development with IFX-1 in severe COVID-19 induced pneumonia. The Company plans to initiate a double-blinded, randomized, placebo-controlled Phase III trial that will be adequately powered for statistical analyses.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
IFX-1 treatment showed a trend in lower 28-day all-cause mortality rate, along with trends of maintained kidney function, faster normalization in lymphocyte counts and greater reduction in LDH in patients with severe COVID-19 pneumonia.
Lead Product(s): Ifx-1
Therapeutic Area: Infections and Infectious Diseases Product Name: IFX-1
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2020
Details:
InflaRx has dosed the first patient in an adaptive randomized controlled clinical study with IFX-1 in patients with severe COVID-19 pneumonia in the Netherlands.
Lead Product(s): Ifx-1
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020
Details:
Two out of the first five patients dosed with IFX-1 achieved complete remission. Dose escalation warranted by pharmacodynamic analysis and approved by relevant authorities in 3 dose cohorts.
Lead Product(s): Ifx-1
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
